FDA Approves Moderna's mRNA Flu Vaccine for Older Adults, Offering New Protection
The Food and Drug Administration (FDA) has approved Moderna's mRNA-based flu vaccine, mFlusiva, marking a significant advancement in flu prevention for adults aged 50 and older. This approval is the first of its kind for a non-COVID-related mRNA vaccine in the United States. The vaccine is initially approved for individuals aged 50 to 64, with further studies planned for those over 65. Clinical trials demonstrated that mFlusiva is 26.6% more effective than traditional flu vaccines. Moderna plans to make the vaccine available at select retailers soon, as other flu vaccines are already arriving in pharmacies for the upcoming vaccination season.